Skip to Main Content

Paper Details

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Target Oncol
5
2021
BRCAm, HRR, Homologous, Homologous Recombination, Metastatic Castration-Resistant Prostate Cancer, PATIENTS, PPP2R2A gene, RPSFTM, mCRPC, olaparib, patients
Author NameAffiliation
Johann S de BonoInstitute of Cancer Research and Royal Marsden Hospital
Maha HussainThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
  • 1 - 3

Datasets

Release 1.2